Pfizer Price to Sales Ratio 2010-2024 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of April 04, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Pfizer P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-04-04 |
23.00 |
|
2.06 |
| 2024-12-31 |
26.10 |
$11.16 |
2.34 |
| 2024-09-30 |
28.03 |
$10.60 |
2.65 |
| 2024-06-30 |
26.73 |
$9.89 |
2.70 |
| 2024-03-31 |
26.11 |
$9.83 |
2.66 |
| 2023-12-31 |
26.69 |
$10.45 |
2.56 |
| 2023-09-30 |
30.34 |
$12.28 |
2.47 |
| 2023-06-30 |
33.18 |
$13.85 |
2.40 |
| 2023-03-31 |
36.51 |
$16.43 |
2.22 |
| 2022-12-31 |
45.44 |
$17.66 |
2.57 |
| 2022-09-30 |
38.48 |
$17.45 |
2.21 |
| 2022-06-30 |
45.75 |
$17.69 |
2.59 |
| 2022-03-31 |
44.81 |
$16.16 |
2.77 |
| 2021-12-31 |
50.72 |
$14.27 |
3.56 |
| 2021-09-30 |
36.62 |
$12.12 |
3.02 |
| 2021-06-30 |
33.04 |
$9.75 |
3.39 |
| 2021-03-31 |
30.27 |
$8.17 |
3.70 |
| 2020-12-31 |
30.43 |
$7.41 |
4.11 |
| 2020-09-30 |
28.44 |
$5.70 |
4.99 |
| 2020-06-30 |
25.10 |
$6.12 |
4.10 |
| 2020-03-31 |
24.80 |
$6.70 |
3.70 |
| 2019-12-31 |
29.47 |
$7.19 |
4.10 |
| 2019-09-30 |
26.77 |
$7.06 |
3.79 |
| 2019-06-30 |
31.98 |
$7.03 |
4.55 |
| 2019-03-31 |
31.07 |
$6.96 |
4.47 |
| 2018-12-31 |
31.66 |
$6.81 |
4.65 |
| 2018-09-30 |
31.72 |
$8.88 |
3.57 |
| 2018-06-30 |
25.89 |
$8.83 |
2.93 |
| 2018-03-31 |
25.08 |
$8.71 |
2.88 |
| 2017-12-31 |
25.36 |
$8.68 |
2.92 |
| 2017-09-30 |
24.77 |
$8.63 |
2.87 |
| 2017-06-30 |
23.08 |
$8.57 |
2.69 |
| 2017-03-31 |
23.28 |
$8.57 |
2.72 |
| 2016-12-31 |
21.88 |
$8.56 |
2.56 |
| 2016-09-30 |
22.59 |
$8.59 |
2.63 |
| 2016-06-30 |
23.29 |
$8.41 |
2.77 |
| 2016-03-31 |
19.43 |
$8.17 |
2.38 |
| 2015-12-31 |
20.95 |
$7.81 |
2.68 |
| 2015-09-30 |
20.22 |
$7.60 |
2.66 |
| 2015-06-30 |
21.42 |
$7.60 |
2.82 |
| 2015-03-31 |
22.04 |
$7.68 |
2.87 |
| 2014-12-31 |
19.56 |
$7.71 |
2.54 |
| 2014-09-30 |
18.41 |
$7.63 |
2.41 |
| 2014-06-30 |
18.32 |
$7.60 |
2.41 |
| 2014-03-31 |
19.65 |
$7.44 |
2.64 |
| 2013-12-31 |
18.58 |
$7.40 |
2.51 |
| 2013-09-30 |
17.29 |
$7.14 |
2.42 |
| 2013-06-30 |
16.73 |
$6.97 |
2.40 |
| 2013-03-31 |
17.09 |
$7.00 |
2.44 |
| 2012-12-31 |
14.72 |
$7.25 |
2.03 |
| 2012-09-30 |
14.46 |
$6.99 |
2.07 |
| 2012-06-30 |
13.26 |
$7.39 |
1.79 |
| 2012-03-31 |
12.93 |
$7.62 |
1.70 |
| 2011-12-31 |
12.23 |
$7.71 |
1.59 |
| 2011-09-30 |
9.89 |
$8.17 |
1.21 |
| 2011-06-30 |
11.39 |
$8.03 |
1.42 |
| 2011-03-31 |
11.13 |
$8.08 |
1.38 |
| 2010-12-31 |
9.49 |
$8.07 |
1.18 |
| 2010-09-30 |
9.21 |
$8.40 |
1.10 |
| 2010-06-30 |
7.57 |
$8.13 |
0.93 |
| 2010-03-31 |
9.01 |
$7.63 |
1.18 |
| 2009-12-31 |
9.46 |
$7.20 |
1.31 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.715B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
